Eli Lilly (LLY) Operating Income (2009 - 2026)

Eli Lilly has reported Operating Income for 18 years, with the latest figure at $9.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 80.35% year-over-year to $9.5 billion; the trailing twelve-month figure through Mar 2026 stood at $33.4 billion (up 77.64% YoY), and the FY2025 full-year result was $29.2 billion, up 80.56% from the prior year.
• Operating Income for Q1 2026 stood at $9.5 billion, up from $8.9 billion in the prior quarter.
• The five-year high for Operating Income was $9.5 billion in Q1 2026, with the low at $1.6 billion in Q1 2023.
• Historically, Operating Income has averaged $4.3 billion across 5 years, with a median of $3.4 billion in 2023.
• Annual changes were most pronounced in 2023 — Operating Income tumbled 37.78% — and 2025, when it jumped 101.07%.
• Eli Lilly's Operating Income stood at $2.1 billion in 2022, then soared by 44.94% to $3.0 billion in 2023, then jumped by 77.35% to $5.3 billion in 2024, then soared by 66.8% to $8.9 billion in 2025, then rose by 6.69% to $9.5 billion in 2026.
• The last three Operating Income figures came in at $9.5 billion (Q1 2026), $8.9 billion (Q4 2025), and $8.0 billion (Q3 2025), per Business Quant data.